Midi Health.

It is 3 a.m. somewhere in California. A 47-year-old woman wakes up soaked in sweat for the eighth night in a row. She has googled "early heart attack symptoms," "perimenopause," and "am I dying." She has an appointment with her primary care doctor in nine days. He will hand her a pamphlet. He will not write a prescription. This is the patient Midi Health was built for - and the patient American medicine kept losing.

For a long time, the menopause economy was a candle aisle at Target. There were teas. There were supplements with names that sounded like yacht companies. There was almost nowhere to get a real prescription from a doctor who knew the literature. Midi Health, the Palo Alto-based virtual clinic that crossed a $1 billion valuation in February 2026, decided this was not a wellness problem. It was a medical problem. Then it built a clinic around that distinction.

Today the company runs a national telehealth practice staffed by more than 500 menopause-trained clinicians, accepts insurance in all 50 states, and has treated more than 230,000 patients. Its $100 million Series D - led by Goodwater Capital with participation from Serena Williams' Serena Ventures, Foresite Capital, GV, Emerson Collective, McKesson Ventures and Felicis - is the largest single round in women's midlife health to date. Investors are not buying a niche. They are buying the realization that there isn't one.

01The Problem They Saw

Roughly 1.3 million American women enter menopause every year. The condition lasts, on average, seven and a half years. Symptoms include hot flashes, sleep collapse, brain fog, anxiety, joint pain, weight redistribution, and a quiet new acquaintance with bone loss. Only about one in five medical schools required menopause training in their OB-GYN residencies as recently as 2019. Most general practitioners have never written a script for hormone replacement therapy in their lives.

The reason isn't malice. It's history. After the 2002 Women's Health Initiative study scared an entire generation of doctors away from hormone therapy with a now-disputed cancer-risk finding, prescriptions dropped by roughly 80 percent. Two decades of nuance and re-analysis have followed. The doctors didn't catch up. The patients went silent. The product category called "menopause" was effectively orphaned.

Joanna Strober - a former private equity investor turned consumer health founder who had previously built the childhood-health company Kurbo - learned this the slow way. She didn't know the word perimenopause when her own symptoms started. She had hot flashes in her mid-forties and night sweats by 47. She spent months searching for a doctor who would actually treat her. She found one. She also found a market.

02The Founders' Bet

Strober assembled a founding team that looked nothing like the standard healthtech roster: COO Sharon Meers (a former Goldman Sachs MD and author), Chief Medical Officer Dr. Kathleen Jordan (an HIV physician who'd spent a career fixing systems for ignored patients), and Chief Brand Officer Jill Herzig (the former editor-in-chief of Redbook and Glamour). Three of the four co-founders had personally been told by a doctor that what they were experiencing was probably stress.

The bet was unglamorous. Build a telehealth clinic - not an app, not a course, not a supplement. Get it credentialed with the biggest commercial insurers, so the visit costs the patient a normal copay instead of a fashionable monthly subscription. Recruit clinicians who actually wanted to specialize in menopause and train them on a single, evidence-led protocol. Make the platform consumer-friendly enough that women who had given up on the medical system would come back.

03The Product

Open the Midi app today and the experience is intentionally undramatic. A questionnaire about symptoms. A scheduled video visit with a clinician usually within days. A care plan that may include hormone therapy, non-hormonal medications, prescription strength supplements formulated in-house, sleep interventions, GLP-1 weight management, or referrals for diagnostic blood work. The whole thing is designed to feel less like a startup and more like the doctor's office you wish you'd had at 25.

Insurance is the trick. Midi has built network contracts with Aetna, BlueCross BlueShield, UnitedHealthcare and others, covering more than 80 percent of US commercial PPO plans and reaching an addressable pool of roughly 45 million women. For employers, Midi sells a benefits package - now used by multiple Fortune 100 companies - that comes without per-employee-per-month fees, which is itself an act of mild defiance in a category addicted to PEPM pricing.

04The Proof

It is one thing to claim a market exists. It is another to fill it. The growth chart below uses publicly disclosed milestones - and it is the kind of curve that makes investors nervous in a good way.

Coverage is part of the moat. Insurance contracts are notoriously slow to negotiate; the larger the panel, the higher the wall against late entrants. Clinical credibility is another piece - Midi has secured NCQA accreditation, the gold standard most consumer health startups quietly skip. And then there is the patient retention number, which the company does not publish but which has been described privately by investors as "embarrassingly sticky."

05The Mission

Strober has been disciplined about not letting the company drift into wellness theater. There are no candles. There are no merchandise drops. There is, however, an expanding clinical scope. The 2025 launch of AgeWell - an insurance-covered longevity program that includes diagnostic bloodwork, annual screenings and personalized protocols - is essentially Midi's way of saying that midlife care doesn't end when the hot flashes do. Bone health, cardiovascular risk, cognition and sexual wellness all belong on the same chart.

The internal phrasing is "patient for life." A woman who comes to Midi for night sweats at 47 might still be a patient at 67, navigating osteoporosis screenings or hormone tapering. That horizon is what makes the unit economics work. It is also what gives the mission its weight: this is not a symptom company. It is a longevity company that happened to start at the door labelled menopause.

06Why It Matters Tomorrow

The corporate world has noticed. In 2023, only 4 percent of US employers offered menopause support. By 2025 that number was projected at 18 percent. Hot flashes are reportedly the leading driver of unscheduled absence among women aged 45 to 55. Companies that figure out how to retain senior women - the demographic most likely to leave the workforce mid-career - are quietly discovering that menopause is a benefits-package conversation as much as a clinical one.

Midi's growth coincides with a broader cultural unmuting. Halle Berry has testified before Congress about menopause. The British government appointed a menopause employment champion. Drew Barrymore, Michelle Obama and Oprah have all done long-form interviews on the subject. The category has gone from unmentionable to ambient. Midi sits at the medical end of that conversation, which is where the prescriptions actually get written.

Back to that woman in California, awake at 3 a.m. In the version of the story that Midi is building, she doesn't wait nine days for a pamphlet. She books a visit on her phone before sunrise. She sees a clinician who knows the literature, gets a prescription her insurance covers, and goes back to sleep two nights later. The hot flashes don't define the next decade of her life. Neither does the silence that used to follow them. The market America forgot turned out to be the largest one hiding in plain sight - and the company that remembered is finally being treated like the unicorn it was always going to be.